Use of a mixture of sodium hyaluronate and chondroitin sulfate for the treatment of osteoarthritis
View Patent ↗This invention is related to the use of the composition formed by sodium hyaluronate and sodium chondroitin sulfate for the treatment of chondral lesions in osteoarthritis, and to the use of such composition in the manufacture of a product for such treatment.
1. A therapeutic method for the treatment of a joint exhibiting degeneration of articular cartilage comprising the intraarticular administration to said joint of a viscous composition comprising a therapeutically effective amount of a mixture of chondroitin sulfate and hyaluronic acid or pharmaceutically acceptable salts thereof.
2. The method of claim 1 , wherein the joint is in a human patient and the degeneration of the cartilage is caused by chondrmalacia or osteoarthritis of grade I or grade II.
3. The method of either claim 1 or claim 2 , wherein the composition comprises a mixture of chondroitin sulfate at a concentration of 0.1 to 50% by weight and sodium hyaluronate at a concentration of 0.1 to 50% by weight.
4. The method of claim 3 , wherein the chondroitin sulfate concentration is from 0.1 to 5.3% by weight and the sodium hyaluroante concentration is from 0.1 to 4.2% by weight of the composition.
5. The method of claim 4 , wherein the composition is a sterile, non-pyrogenic, viscoelastic solution comprising a mixture of chondroitin sulfate and sodium hyaluronate in a ratio of about 4 parts by weight chondroitin sulfate to about 3 parts by weight sodium hyaluronate.
6. The method of claim 5 , wherein the concentration of chondroitin sulfate is about 40 mg/ml and the concentration of sodium hyaluronate is about 30 mg/ml.
7. The method of claim 6 , wherein the chondroitin sulfate has a molecular weight of 20,000 to 50,000 daltons, the sodium hyaluronate has a molecular weight of 500,000 to 1,000,000 daltons, and the composition has a viscosity of 20,000 to 60,000 cps.
8. The method of claim 1 , wherein one or more doses of between 0.5 and 1.5 cubic centimeters of the viscoelastic composition are administered to the affected joint.
9. The method of claim 8 , wherein 2 to 6 doses of the viscoelastic composition are administered over 1 to 3 months.
10. The method of claim 9 , wherein 2 to 4 doses of the viscoelastic composition are administered at 10 to 20 day intervals.
11. The method of claim 10 , wherein 3 doses of the viscoelastic composition are administered at 15 day intervals.
12. The therapeutic method according to claim 8 , wherein the joint is a human joint selected from the group formed by the following joints: i) knees, shoulders and sacroiliac; ii) coxofemoral, ankles and elbows; and iii) interphalangeal and wrists.
13. The therapeutic method according to claim 12 , wherein each dose of the viscoelastic composition is 1.5 cubic centimeters of the composition for the knee, shoulder or sacroiliac joints.
14. The therapeutic method according to claim 8 , wherein each dose of the viscoelastic composition is 0.75 cubic centimeters of the composition for the coxofemoral, ankle or elbow joints.
15. The therapeutic method according to claim 8 , wherein each dose of the viscoelastic composition is 0.5 cubic centimeters of the composition for the interphalangeal or wrist joints.
16. A method of repairing or regenerating cartilage in a mammalian joint characterized by cartilage degeneration or trauma, comprising the intraaticular administration of a mixture of chondroitin sulfate and hyaluronic acid or pharmaceutically acceptable salts thereof.